MX374191B - Derivados de nucleósido sustituidos con 4´ -difluorometilo como inhibidores de la replicación de arn de la influenza. - Google Patents

Derivados de nucleósido sustituidos con 4´ -difluorometilo como inhibidores de la replicación de arn de la influenza.

Info

Publication number
MX374191B
MX374191B MX2016010105A MX2016010105A MX374191B MX 374191 B MX374191 B MX 374191B MX 2016010105 A MX2016010105 A MX 2016010105A MX 2016010105 A MX2016010105 A MX 2016010105A MX 374191 B MX374191 B MX 374191B
Authority
MX
Mexico
Prior art keywords
inhibitors
rna replication
nucleoside derivatives
influenza rna
substituted nucleoside
Prior art date
Application number
MX2016010105A
Other languages
English (en)
Other versions
MX2016010105A (es
Inventor
Klaus G Klumpp
Mark Smith
Original Assignee
Riboscience Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Riboscience Llc filed Critical Riboscience Llc
Publication of MX2016010105A publication Critical patent/MX2016010105A/es
Publication of MX374191B publication Critical patent/MX374191B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A61K31/708—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid having oxo groups directly attached to the purine ring system, e.g. guanosine, guanylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • C07H19/213—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids containing cyclic phosphate
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H7/00—Compounds containing non-saccharide radicals linked to saccharide radicals by a carbon-to-carbon bond
    • C07H7/06—Heterocyclic radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La solicitud describe derivados de nucleósido de la Fórmula I como inhibidores de la replicación de ARN de la influenza. En particular, la solicitud describe el uso de derivados de nucleósido de purina y pirimidina de la Fórmula I como inhibidores de la replicación de ARN de la influenza y composiciones farmacéuticas que contienen tales compuestos. (ver Fórmula).
MX2016010105A 2014-02-06 2015-02-06 Derivados de nucleósido sustituidos con 4´ -difluorometilo como inhibidores de la replicación de arn de la influenza. MX374191B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461936569P 2014-02-06 2014-02-06
PCT/US2015/014762 WO2015120237A2 (en) 2014-02-06 2015-02-06 4'-difluoromethyl substituted nucleoside derivatives as inhibitors of influenza rna replication

Publications (2)

Publication Number Publication Date
MX2016010105A MX2016010105A (es) 2016-11-15
MX374191B true MX374191B (es) 2025-03-05

Family

ID=53774368

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016010105A MX374191B (es) 2014-02-06 2015-02-06 Derivados de nucleósido sustituidos con 4´ -difluorometilo como inhibidores de la replicación de arn de la influenza.

Country Status (20)

Country Link
US (2) US9370569B2 (es)
EP (1) EP3102215B1 (es)
JP (1) JP6581100B2 (es)
KR (1) KR102327464B1 (es)
CN (1) CN105979951B (es)
AR (1) AR099312A1 (es)
AU (1) AU2015213791B2 (es)
CA (1) CA2945693C (es)
CL (1) CL2016001973A1 (es)
CR (1) CR20160400A (es)
EA (1) EA033866B1 (es)
IL (1) IL246929B (es)
MA (1) MA39317A1 (es)
MX (1) MX374191B (es)
PE (1) PE20170203A1 (es)
PH (1) PH12016501567B1 (es)
SG (1) SG11201606368WA (es)
TW (1) TWI620755B (es)
WO (1) WO2015120237A2 (es)
ZA (1) ZA201605979B (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015120237A2 (en) * 2014-02-06 2015-08-13 Riboscience Llc 4'-difluoromethyl substituted nucleoside derivatives as inhibitors of influenza rna replication
PL3102568T3 (pl) 2014-02-06 2019-01-31 Heptares Therapeutics Limited Bicykliczne związki aza w postaci agonistów receptorów muskarynowych m1
MA41213A (fr) 2014-12-19 2017-10-24 Alios Biopharma Inc Nucléosides substitués, nucléotides et analogues de ceux-ci
CN106543220A (zh) 2015-09-16 2017-03-29 博瑞生物医药（苏州）股份有限公司 氨基磷酸酯化合物及其制备方法和晶体
CN112156102B (zh) * 2015-09-16 2023-10-03 济南高合医疗科技有限公司 一种nuc-1031单一异构体的晶型及其制备方法
JP2020529994A (ja) * 2017-07-31 2020-10-15 ジャニュアリー セラピューティクス，インク． 有機リン酸誘導体
CN111434671B (zh) * 2019-01-11 2023-07-11 凯思凯迪（上海）医药科技有限公司 肝脏特异性ampk激动剂及其制法和应用
JP2020164521A (ja) * 2019-03-29 2020-10-08 国立大学法人 長崎大学 抗ウィルス薬
CN114072407A (zh) * 2019-04-02 2022-02-18 阿里戈斯治疗公司 靶向prmt5的化合物
WO2020223530A1 (en) * 2019-04-30 2020-11-05 Cure Biopharma Inc. Gemcitabine prodrugs
EP3962919A4 (en) * 2019-05-03 2023-06-28 Terns Pharmaceuticals, Inc. Compounds for treating cancer
TWI874791B (zh) 2020-02-18 2025-03-01 美商基利科學股份有限公司 抗病毒化合物
TWI794742B (zh) 2020-02-18 2023-03-01 美商基利科學股份有限公司 抗病毒化合物
EP4106876B1 (en) 2020-02-18 2025-09-17 Gilead Sciences, Inc. Antiviral compounds
US12274700B1 (en) 2020-10-30 2025-04-15 Accencio LLC Methods of treating symptoms of coronavirus infection with RNA polymerase inhibitors
KR102923359B1 (ko) 2021-04-16 2026-02-05 길리애드 사이언시즈, 인코포레이티드 아미드를 사용한 카르바뉴클레오시드를 제조하는 방법
WO2022266384A1 (en) * 2021-06-17 2022-12-22 Terns Pharmaceuticals, Inc. Methods for treating cancer
EP4387977A1 (en) 2021-08-18 2024-06-26 Gilead Sciences, Inc. Phospholipid compounds and methods of making and using the same
JP2025509635A (ja) * 2022-03-15 2025-04-11 ローム・セラピューティクス・インコーポレイテッド 疾患を治療するための化合物及び方法
WO2024103016A1 (en) * 2022-11-11 2024-05-16 Rome Therapeutics, Inc. 4'-halomethyl-cytidine phosphoramidates and related compounds and their use in treating medical conditions
CN119837893B (zh) * 2025-03-24 2025-07-04 中国农业大学 5-氟-2′-脱氧胞苷在制备抗菌药物中的用途

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5192749A (en) * 1990-05-21 1993-03-09 Syntex (U.S.A.) Inc. 4'-substituted nucleosides
ATE491459T1 (de) * 2000-10-18 2011-01-15 Pharmasset Inc Modifizierte nukleoside zur behandlung von virusinfektionen und abnormaler zellulärer proliferation
US7105499B2 (en) 2001-01-22 2006-09-12 Merck & Co., Inc. Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase
GB0114286D0 (en) * 2001-06-12 2001-08-01 Hoffmann La Roche Nucleoside Derivatives
US20040229840A1 (en) 2002-10-29 2004-11-18 Balkrishen Bhat Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase
TW201305185A (zh) 2010-09-13 2013-02-01 Gilead Sciences Inc 用於抗病毒治療之２’－氟取代之碳－核苷類似物
AU2011305652B2 (en) 2010-09-22 2016-10-20 Janssen Biopharma, Inc. Azido nucleosides and nucleotide analogs
SG10201610936RA (en) 2011-12-22 2017-02-27 Alios Biopharma Inc Substituted nucleosides, nucleotides and analogs thereof
AU2013232378B2 (en) * 2012-03-13 2017-09-28 Gilead Sciences, Inc. 2'- substituted carba-nucleoside analogs for antiviral treatment
CN104203253A (zh) * 2012-03-21 2014-12-10 艾丽奥斯生物制药有限公司 取代的核苷、核苷酸及其类似物
US9441007B2 (en) 2012-03-21 2016-09-13 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
GEP20176800B (en) 2012-05-22 2018-01-10 Idenix Pharmaceuticals Llk D-amino acid compounds for liver disease
US9211300B2 (en) 2012-12-19 2015-12-15 Idenix Pharmaceuticals Llc 4′-fluoro nucleosides for the treatment of HCV
CN110684067A (zh) 2012-12-21 2020-01-14 艾丽奥斯生物制药有限公司 取代的核苷和核苷酸
US9815864B2 (en) * 2013-06-26 2017-11-14 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
AU2014331863C1 (en) * 2013-10-11 2019-05-16 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
WO2015120237A2 (en) * 2014-02-06 2015-08-13 Riboscience Llc 4'-difluoromethyl substituted nucleoside derivatives as inhibitors of influenza rna replication

Also Published As

Publication number Publication date
CN105979951B (zh) 2020-12-25
JP2017506229A (ja) 2017-03-02
PH12016501567A1 (en) 2016-09-14
US9370569B2 (en) 2016-06-21
US10092649B2 (en) 2018-10-09
CN105979951A (zh) 2016-09-28
PH12016501567B1 (en) 2023-12-06
TW201538517A (zh) 2015-10-16
AU2015213791A1 (en) 2016-09-08
IL246929B (en) 2019-09-26
IL246929A0 (en) 2016-09-29
KR20160145542A (ko) 2016-12-20
EA201691554A1 (ru) 2016-12-30
TWI620755B (zh) 2018-04-11
ZA201605979B (en) 2024-10-30
AU2015213791B2 (en) 2019-11-14
EP3102215A4 (en) 2018-01-24
PE20170203A1 (es) 2017-03-16
EA033866B1 (ru) 2019-12-03
KR102327464B1 (ko) 2021-11-16
HK1225617A1 (zh) 2017-09-15
WO2015120237A3 (en) 2015-11-05
SG11201606368WA (en) 2016-09-29
AR099312A1 (es) 2016-07-13
EP3102215A2 (en) 2016-12-14
NZ723551A (en) 2020-09-25
MX2016010105A (es) 2016-11-15
JP6581100B2 (ja) 2019-09-25
EP3102215B1 (en) 2021-06-16
CR20160400A (es) 2016-11-07
US20150225441A1 (en) 2015-08-13
US20170296664A1 (en) 2017-10-19
MA39317A1 (fr) 2018-01-31
WO2015120237A2 (en) 2015-08-13
CL2016001973A1 (es) 2017-02-17
CA2945693C (en) 2020-06-16
CA2945693A1 (en) 2015-08-13

Similar Documents

Publication Publication Date Title
MX374191B (es) Derivados de nucleósido sustituidos con 4´ -difluorometilo como inhibidores de la replicación de arn de la influenza.
UA111804C2 (uk) ПОХІДНІ ПІРОЛО[2,3-d]ПІРИМІДИНУ ЯК ІНГІБІТОРИ ЯНУС-ЗАЛЕЖНИХ КІНАЗ (JAK)
CL2016001895A1 (es) Compuestos
BR112017013491A2 (pt) compostos de pirimidina fundida para o tratamento de hiv
MD4650B1 (ro) Derivaţi de chinazolină utilizaţi în tratamentul HIV
UY36265A (es) “derivados de pirrolo[2,3-d]pirimidina”.
BR112017002811A2 (pt) compostos de pirrolopirimidina usados como agonista de tlr7
CL2015003686A1 (es) Derivados de pirrolo[3,2-d]pirimidina para el tratamiento de infecciones víricas y otras enfermedades
CO2017008403A2 (es) Derivados de nucleósidos sustituidos útiles como agentes antineoplásicos
CL2017003107A1 (es) Derivados de 2-(pirazolopiridin-3-il)pirimidina como inhibidores de jak
CL2015002335A1 (es) Derivados de 2-aminopirimidina para el tratamiento de infecciones víricas.
MX381487B (es) Ciertos inhibidores de la proteina quinasa.
BR112017013440A2 (pt) compostos de isoquinolina para o tratamento de hiv
ECSP18074962A (es) Derivados de aminotiazol útiles como agentes antivíricos
CL2016003214A1 (es) Derivados de la indolizina como inhibidores de las fosfoinositido-3 quinasas
EA201591406A1 (ru) C-19 модифицированные тритерпеноиды с ингибиторной активностью созревания вич
MX374555B (es) Derivados de pirimidina como inhibidores de tirosina cinasa de bruton (btk) y usos de los mismos.
MX395032B (es) Ciertos inhibidores de la proteína quinasa.
MX382726B (es) Compuestos de hidroxil purinas y aplicaciones de estos
PH12015502589A1 (en) 4`-azido, 3`-deoxy-3`-fluoro substituted nucleoside derivatives
DOP2018000049A (es) Compuestos para uso en aplicaciones antibacterianas
AR108616A1 (es) Formulación combinada de tres compuestos antivirales
LV14852A (lv) Triazolilpurīna atvasinājumi kā pretvīrusu preparāti

Legal Events

Date Code Title Description
FG Grant or registration